Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-…
Several effective anti-inflammatory agents and bronchodilators are available for controlling mild or moderate asthma. However, despite the availability of long-acting muscarinic antagonists (LAMAs…
Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of…
Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent…
Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval…
Major depressive disorder is a chronic drug-treated condition, and treatment of it is ingrained with generic therapies. However, many of these therapies suffer from shortcomings in efficacy and/or…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Multiple myeloma remains an incurable hematological malignancy despite the availability of numerous treatment options. Resistance to therapy is the primary challenge associated with the disease’…
No disease-modifying agents have been developed to treat myelodysplastic syndromes (MDS). All pharmacological approaches to treat the disease—growth factor stimulants (e.g., erythropoietin-…
Diabetic macular edema (DME) is caused by diabetes and is characterized by leaking fluid from abnormal blood vessels in the eye; this fluid can lead to swelling of the macula and visual impairment…
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…
Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs where available) are the mainstay of biological treatment for moderate to…
Treatment of chronic spontaneous and chronic inducible urticaria is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and off-label (e.g., DMARDs,…
With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…
With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…